-
European Journal of Cancer & Clinical... May 1985The comparative gonadal toxicity following two equally effective and non-cross-resistant regimens (MOPP and ABVD) was prospectively evaluated in 53 males with Hodgkin's... (Clinical Trial)
Clinical Trial Comparative Study Randomized Controlled Trial
The comparative gonadal toxicity following two equally effective and non-cross-resistant regimens (MOPP and ABVD) was prospectively evaluated in 53 males with Hodgkin's disease. The median age was 29 yr (range 16-45). MOPP produced azoospermia in 28/29 patients (97%) while ABVD induced oligoazoospermia in 13/24 patients (54%). Follicle-stimulating hormone levels were consistently and significantly increased after MOPP while their median value remained within normal range after ABVD. Sperm count was repeated in 34 patients. Recovery of spermatogenesis occurred in 3/21 cases treated with MOPP and in all 13 cases given ABVD. Present findings confirm that the two alkylating agents, mechlorethamine and procarbazine, included in the MOPP regimen cause sterility in most patients while the drugs included in ABVD are not associated with permanent gonadal dysfunction.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Luteinizing Hormone; Male; Mechlorethamine; Middle Aged; Oligospermia; Prednisone; Procarbazine; Prospective Studies; Testosterone; Vinblastine; Vincristine
PubMed: 2408897
DOI: 10.1016/0277-5379(85)90088-4 -
Cancer Treatment Reviews Dec 1984
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Combined Modality Therapy; Drug Resistance; Hodgkin Disease; Humans; Mechlorethamine; Neoplasms, Multiple Primary; Neoplasms, Radiation-Induced; Prednisone; Procarbazine; Prognosis; Vincristine
PubMed: 6549501
DOI: 10.1016/0305-7372(84)90030-6 -
Acta Haematologica 1989The incidence of relapses and second malignant neoplasms was investigated in a group of 148 patients with bad-risk stage II, or stage III and IV Hodgkin's disease...
The incidence of relapses and second malignant neoplasms was investigated in a group of 148 patients with bad-risk stage II, or stage III and IV Hodgkin's disease treated with a MOPP-modified protocol between 1973 and 1979. Sixty-eight patients received chemotherapy alone, 80 a combined modality treatment including radiotherapy. One hundred and twelve patients achieved complete remission with induction therapy. Thirty-six patients relapsed 3-120 months (median 27 months) after the induction program with a 10-year cumulative risk of relapse of 33.6%. Seven out of 112 complete responders developed a second malignancy 65-145 months from the start of therapy; one more neoplasm has been recorded in a patient with active Hodgkin's disease. Survival after diagnosis of second malignant neoplasm did not exceed 12 months. The cumulative risk of developing a second malignancy was 6.2% at 10 years. The free-from-failure survival was 49.2% at 10 years, being 64.7% for patients achieving complete remission and 92.4% for long-term complete responders. Although an increased number of second malignant neoplasms may occur in patients treated for Hodgkin's disease, the high risk of early relapse, together with the limited effectiveness of salvage therapy, suggests that intensive induction programs should be carried out in patients with advanced or poor-prognosis Hodgkin's disease in order to achieve long-lasting complete remission.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasm Staging; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine; Vincristine
PubMed: 2511719
DOI: 10.1159/000205373 -
Journal of the National Cancer Institute Jul 2003
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Incidence; Mechlorethamine; Menopause, Premature; Neoplasms, Second Primary; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Vinblastine; Vincristine
PubMed: 12837820
DOI: 10.1093/jnci/95.13.928 -
American Journal of Clinical Oncology Jun 1982Thirty-six patients with advanced Hodgkin's disease who were treated primarily with MOPP were evaluated to determine the reasons for MOPP failure. Complete remission was...
Thirty-six patients with advanced Hodgkin's disease who were treated primarily with MOPP were evaluated to determine the reasons for MOPP failure. Complete remission was achieved in 22 (61%) of the patients, and the predicted 5-year survival rate for all patients is 60%. Reasons for the failure of MOPP to cure patients in this series included: 1) Idiosyncratic drug reactions in 2 patients (6%). MOPP was discontinued after one cycle because of drug-related hepatitis or skin rash; 2) Resistant disease in 8 patients (22%). Primary treatment failure was significantly associated with the presence of B symptoms (p = .005) and age greater than 40 years (p = .02); 3) Death from complicating infection in 5 patients (14%). Four patients died without evidence of Hodgkin's disease while responding to MOPP from pneumocystis pneumonia, viral pneumonia, bacterial pneumonia, or bacterial septicemia. One patient died in complete remission from sudden, overwhelming sepsis; 4) Relapse from complete remission in 4 patients (11%). All patients who relapsed had deviations from the planned dose or timing of MOPP. Remission duration was shorter (p = .06) in patients with documented deviations in MOPP administration than in patients without such changes. It appears that new treatment approaches are needed for patients with B symptoms, and that failure to deliver MOPP on schedule in the planned dose increases the risk of relapse.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Prednisone; Procarbazine; Vincristine
PubMed: 6896261
DOI: 10.1097/00000421-198206000-00014 -
The Medical Journal of Australia Jan 1986
Review
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Therapy, Combination; Dyspnea; Fluorouracil; Hodgkin Disease; Humans; Hypercalcemia; Leukemia; Leukemia, Lymphoid; Lymphoma; Mechlorethamine; Melphalan; Methotrexate; Multiple Myeloma; Palliative Care; Prednisone; Procarbazine; Receptors, Glucocorticoid; Vinblastine; Vincristine; Vomiting
PubMed: 2417096
DOI: No ID Found -
Cancer Aug 1983The menstrual cycle, pregnancies and offspring were studied before and after MOPP therapy (3 or 6 cycles) in women treated for Hodgkin's disease between 1972 and 1976....
The menstrual cycle, pregnancies and offspring were studied before and after MOPP therapy (3 or 6 cycles) in women treated for Hodgkin's disease between 1972 and 1976. All were between 16 and 45 years of age at diagnosis; none received subdiaphragmatic irradiation. This study was carried out through a questionnaire. Before treatment, all patients had normal menses; 72 pregnancies occurred; 61 children were born, 2 with minor abnormalities. After therapy, oligo or amenorrhea occurred in 26.4% of the patients. This percentage was different according to the age at therapy: 4.8% before age 30, 61.5% after age 30 (P less than 0.001); 50 women (73.6%) continued to menstruate normally, 22 of whom had 30 pregnancies; 22 children were born, 1 with a minor abnormality. All have normal physical and intellectual development. For the 73.6% of women who continued to menstruate, MOPP therapy seems to have no impact on fertility, pregnancies, and offspring.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Mechlorethamine; Menstruation; Middle Aged; Parity; Prednisone; Pregnancy; Procarbazine; Prospective Studies; Surveys and Questionnaires; Vincristine
PubMed: 6688036
DOI: 10.1002/1097-0142(19830801)52:3<435::aid-cncr2820520308>3.0.co;2-1 -
The New England Journal of Medicine Apr 1993
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Vinblastine; Vincristine
PubMed: 7680765
DOI: 10.1056/NEJM199304083281417 -
Pediatric Hematology and Oncology 2000The aim of this study was to investigate the impact of therapy on long-term gonadal function of young people cured of childhood lymphomas and to assess whether a...
The aim of this study was to investigate the impact of therapy on long-term gonadal function of young people cured of childhood lymphomas and to assess whether a prepubertal state during the treatment protects the gonads from chemotherapy and/or radiotherapy late effects. Clinical evaluation, semen analysis, and endocrine status were studied in 20 survivors of childhood lymphomas. Five patients received Inverted Y radiotherapy, 2320 cGy (1550-4000); all 20 received chemotherapy as follows: MOPP/ABVD protocol, 9 patients; COMP protocol, 5 patients; MOPP protocol, 3 patients; other protocols, 3 patients. Semen analysis results were as follows: normal values, 4/20 patients; oligospermia, 8/20 patients; azoospermia, 8/20 patients; FSH above normal level, 10/20 patients; 4/5 who received Inverted Y irradiation were azoospermic and 1 was severely oligospermic. Treatment damage to the testis involves tubular germinal elements. Radiotherapy and chemotherapy combinations that included nitrogen mustard or cyclophosphamide were associated with high rates of oligospermia and azoospermia. MOPP/ABVD combination did not have a significant better outcome of sperm counts compared to MOPP alone. Age at chemotherapy did not correlate with the sperm count; hence a prepubertal state did not protect the gonad from the late effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Doxorubicin; Fertility; Follow-Up Studies; Gonadal Steroid Hormones; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Oligospermia; Prednisone; Procarbazine; Puberty; Radiotherapy; Radiotherapy Dosage; Sperm Count; Survivors; Time Factors; Vinblastine; Vincristine
PubMed: 10779990
DOI: 10.1080/088800100276415 -
Journal of Clinical Oncology : Official... Jan 2014
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Europe; History, 20th Century; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Procarbazine; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine
PubMed: 24441526
DOI: 10.1200/JCO.2013.53.1194